Physician profile
Pascal Dabel
NPI 1033306592
$4,965.31
in general payments reported to CMS, 2019-2025
34 companies · $857 in 2025
The $857 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $320 · 2021: $366 · 2022: $774 · 2023: $881 · 2024: $921 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,591 · Education: $67.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,590.70 |
| Education | $67.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $968.20 | 2019-2025 | Lokelma, Farxiga |
| Glaxosmithkline, LLC. | $560.26 | 2022-2025 | Benlysta, Jesduvroq |
| Aurinia Pharma U.S., INC. | $460.51 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $430.33 | 2019-2023 | Krystexxa |
| Amgen INC. | $419.04 | 2023-2025 | Krystexxa, Tavneos, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $385.26 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $361.85 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $184.85 | 2021-2025 | |
| Akebia Therapeutics INC | $158.11 | 2019-2025 | Vafseo |
| Veloxis Pharmaceuticals, INC. | $100.78 | 2025 | Envarsus |
| Henry Schein, INC. | $88.33 | 2024 | |
| Opko Pharmaceuticals, LLC | $88.13 | 2019-2025 | Rayaldee |
| Travere Therapeutics, INC. | $87.41 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $82.61 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $77.18 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.89 | 2025 | Jardiance |
| Calliditas Therapeutics US INC. | $70.81 | 2023-2025 | Tarpeyo |
| Nxstage Medical, INC. | $45.11 | 2019 | |
| Genzyme Corporation | $42.78 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $35.81 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $35.42 | 2022 | |
| Lilly USA, LLC | $32.20 | 2024 | Jardiance |
| Mallinckrodt Enterprises LLC | $31.31 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.56 | 2022 | |
| Ascendis Pharma Endocrinology INC | $27.51 | 2025 | Yorvipath |
| Ani Pharmaceuticals, INC. | $26.44 | 2025 | Purified Cortrophin Gel |
| Ardelyx, INC. | $25.55 | 2025 | Ibsrela |
| Rockwell Medical, INC. | $20.17 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.90 | 2021 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pascal Dabel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.